Abstract 2623
Background
The clinical relevance of mismatch repair deficiency (MMRd) in patients with early-stage cancer remains unclear. Our goal was to investigate the prognostic role of MMRd in patients with colorectal and endometrial cancer.
Methods
From 05/1990 to 03/2013, formalin-fixed paraffin-embedded primary tumors were prospectively collected from patients with early-stage colorectal (991) and endometrial (167) cancer, referred to the Departments of Medical Oncology affiliated with the Hellenic Cooperative Oncology Group. Protein expression of MMR proteins was evaluated by immunohistochemistry. The primary outcome measure was overall survival (OS).
Results
Overall, 1158 patients were included (median age, 64 years). Stage III disease was diagnosed in 58% and 19% of patients with colorectal and endometrial cancer, respectively. All patients with colorectal cancer but only 13% of those with endometrial cancer received adjuvant treatment. MMRd was observed in 114 (11.5%) of colorectal and 80 (48%) of endometrial tumors. MMRd was associated with younger age at diagnosis (62 vs. 60y, Mann-Whitney, p = 0.003), higher tumor grade (26.3% vs 16.5%, chi-square, p < 0.001) and lower tumor stage (72% vs. 42.6%, p < 0.001). Colorectal MMRd tumors were more likely right-sided (64.6% vs. 27.2%, p < 0.001), and with a mucinous component (63.7% vs. 41.4%, p < 0.001). Endometrial MMRd tumors were more often endometrioid (74/144, 51.4%) than serous/clear cell (3/15, 20%) carcinomas (p = 0.020). Compared to MMR proficiency, MMRd was associated with improved OS in the entire cohort (HR = 0.66, 95% CI 0.47-0.92, Wald’s p = 0.013) and in patients with endometrial cancer, (HR = 0.39, 95% CI 0.20-0.77, p = 0.006) but not in patients with colorectal cancer (HR = 0.73, 95% CI 0.49-1.09, p = 0.120). In multivariate analysis adjusting for tumor type, stage and grade, MMRd maintained its favorable prognostic significance in the entire cohort (Wald’s p = 0.014) and in patients with endometrial cancer (p = 0.017).
Conclusions
MMRd is associated with improved outcomes in patients with early-stage endometrial cancer, but not in patients with early-stage colorectal cancer.
Clinical trial identification
Legal entity responsible for the study
Hellenic Cooperative Oncology Group.
Funding
Hellenic Cooperative Oncology Group Internal Research Grant.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract